Evaluate the Distribution and Dynamic Behavior of TH-SC01 Cells in Vivo in Patients With Perianal Fistula

Exclusion Criteria17

• Subjects with active infection evaluated by the investigator.
• Subjects with Crohn\'s disease requiring immediate therapy.
• Subjects with abscess or collections \>2 cm.
• Subjects with rectal and/or anal stenosis and/or active proctitis.
• Subjects who treated with systemic steroids in the 4 weeks prior to stem cells administration.
• Subjects with abnormal laboratory results: liver function: total bilirubin \>=1.5 × ULN, and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) \>=2 × ULN; renal function: creatinine clearance below 60 mL/minute calculated using Cockcroft-Gault formula or by serum creatinine \>=1.5 × upper limit of normal (ULN).
• Subjects with malignant tumors or a history of malignant tumors.
• Subjects with severe, progressive, uncontrolled hepatic, hematological, gastrointestinal (except Crohn\'s disease), endocrine, pulmonary, cardiac, neurological, psychiatric, or cerebral diseases.
• Serum virology test (HBeAg, HCV antibody, HIV antibody, Treponema pallidum antibody) positive.
• Subjects allergic to Human serum albumin, human platelet lysate, gentamicin sulfate, anesthetic drug
• Subjects who has received stem cells therapy.
• Subjects who has major surgery or severe trauma within 6 months prior to the screening period.
• Subjects who has received any investigational drug within 3 months prior to the screening.
• Subjects deemed inappropriate by the investigator to participate in this clinical trial.
• The female participant who is pregnant, or is lactating.
• Not suitable for PET/CT examination.
• Participants considered inappropriate to participate in this clinical trial